-4.36%
Today
Loading 1D prices…
Company profile
Tenax Therapeutics, Inc., a development-stage pharmaceutical company, develops novel cardiopulmonary therapies in the United States. It develops TNX-101, TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension in heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is headquartered in Chapel Hill, North Carolina.
Sector
Health Care
Industry
Biotechnology: Pharmaceutical Preparations
Exchange
Nasdaq
Display currency
USD
Location
Chapel Hill, NC, United States
Employees
14
Fiscal year end
1231
CIK
34956
Session & valuation
Latest annual period
Deterministic peer set
Exact regulatory industry matches, ranked by nearest market capitalization.
| Company | Market cap | Revenue | Net margin | Diluted EPS | Today | Consensus |
|---|---|---|---|---|---|---|
| RNTXRein Therapeutics Inc. Common Stock | $67.7M | $0.00 | — | -$1.96 | +1.31% | Buy |
| APLMApollomics Inc. Class A Ordinary Shares | $67.6M | $8.5M | -128.69% | -$52.80 | -2.75% | Unrated |
| YARWYarrow Bioscience Inc. Common Stock | $72.1M | $570K | -4646.14% | -$0.62 | -5.03% | Hold |
| PLRXPliant Therapeutics Inc. Common Stock | $72.4M | $0.00 | — | -$2.43 | +3.54% | Sell |
| XBITXBiotech Inc. Common Stock | $66.8M | $0.00 | — | -$1.49 | +0.92% | Unrated |